Neuronetics (STIM) Cash & Equivalents (2017 - 2026)

Neuronetics (STIM) has reported Cash & Equivalents for 10 consecutive years, with $5.8 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash & Equivalents rose 475.0% year-over-year to $5.8 million; the TTM figure through Mar 2026 stood at $5.8 million (up 475.0% YoY), while the FY2025 annual figure was $6.0 million, up 500.0% from the prior year.
• Cash & Equivalents eased to $5.8 million in Q1 2026 per STIM's latest filing, from $6.0 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $80.8 million in Q1 2022 and bottomed at $1.0 million in Q4 2024.
• Historically, Cash & Equivalents has averaged $37.4 million across 5 years, with a median of $42.6 million in 2024.
• Annual changes were most pronounced in 2024 — Cash & Equivalents slumped 98.32% — and 2025, when it surged 500.0%.
• Neuronetics' Cash & Equivalents stood at $70.3 million in 2022, then retreated by 15.16% to $59.7 million in 2023, then plunged by 98.32% to $1.0 million in 2024, then soared by 500.0% to $6.0 million in 2025, then fell by 4.17% to $5.8 million in 2026.
• Business Quant data shows STIM's Cash & Equivalents at $5.8 million in Q1 2026, $6.0 million in Q4 2025, and $6.5 million in Q3 2025.